AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 151 min read$COO

Cooper Companies (NASDAQ: COO) director bought more stock in a single trade

Cooper Companies (COO) director Lawrence Erik Kurzius bought 10,000 shares of common stock on September 14, 2026, at $53.915 per share, totaling $539,000. He now directly holds 21,099 shares. The purchase was not part of a Rule 10b5-1 trading plan.

Original reporting
stocktitan.net
Published Sep 15, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$COO
Neutral
medium confidence
Mentioned
$COO
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$COONeutralLow
01

Why it matters

The filing provides fresh, primary‑source information about insider activity, but the modest size limits trading relevance.

02

Market read

New insider purchase adds a data point for traders monitoring COO, but impact is expected to be minimal.

03

What to watch

Potential upcoming product launches or trial data could be the real driver, not the insider trade.

Relevance 4/10Novelty 4/10Timing: September 14, 2026 purchase (post‑market)

Background

Cooper Companies (NASDAQ: COO) disclosed a Form 4 filing showing a director's recent stock purchase.

Company-level read

Ticker impact

$COONeutralMedium confidence
Context

Director Lawrence Erik Kurzius purchased 10,000 shares of Cooper Companies at $53.915 per share, increasing his holding to 21,099 shares.

Expected impact

Minor upside pressure, potential 1‑2% move if market perceives the buy positively.

Evidence & confidence

Insider buys are generally viewed positively, yet the transaction amount is small relative to market cap, limiting material effect.

Market effects

Sector

None significant; Cooper Companies operates in medical devices and fertility, sector unchanged.

Regional

U.S. market only; no broader regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing; investors should not infer strong bullish sentiment.

Key entities

  • Director
    Lawrence Erik Kurzius

    Director of Cooper Companies who bought 10,000 shares.

  • Company
    Cooper Companies, Inc.

    Medical device and fertility company (NASDAQ: COO).

Read at source← All news

Related articles

SEP 21
$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

insidermonkey.com2 min
SEP 14
$COOMedAI 8/10

The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.

finance.yahoo.com3 min
SEP 11
$COOMedAI 8/10

Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision

Cooper Companies (COO) reported Q3 FY2026 revenue of $1.066B, up 1%, and adjusted EPS of $1.15, up 4%. The company spent $339.1M on share buybacks and has $1.5B remaining in repurchase capacity. Fertility segment growth and strong cash flow offset weakness in CooperVision, which saw flat organic growth and revenue declines in Americas and Asia Pacific. Gross margin improved to 67% on a GAAP basis, while adjusted operating margin rose 30 basis points to 26%.

yahoo.com2 min
SEP 11
$COOMed

Why Cooper, Freeport-McMoRan, and Baker Hughes Plunged

Cooper Companies (COO) fell 14.67% after reporting Q3 revenue of $1.07B and Q4 guidance below estimates. Freeport-McMoRan (FCX) dropped 6.59% due to White House uncertainty on copper tariffs. Baker Hughes (BKR) declined 6.66% despite raising its full-year revenue guidance to $28.5B-$30.3B.

baystreet.ca2 min
SEP 11
$COOMedAI 8/10

COO Q2 Deep Dive: Inventory Actions and Strategic Review Shape Guidance

CooperCompanies reported Q2 revenue of $1.07B (flat YoY, 2.9% miss) and adjusted EPS of $1.15 (2.7% beat). Full-year guidance was lowered to $4.24B revenue and $4.53 EPS. The company reduced U.S. inventory and retained CooperSurgical after a strategic review. Management plans to invest in sales and R&D, aiming for future growth and improved margins.

yahoo.com2 min
SEP 10
$COOMedAI 8/10

Why is CooperCompanies Stock Down 15% Today?

CooperCompanies (COO) shares dropped 13.9% after Q3 earnings beat estimates but Q4 guidance fell short of expectations. The company also decided to retain CooperSurgical, removing a potential deal catalyst. U.S. distributor destocking is expected to continue impacting CooperVision's Q4 performance.

aol.com2 min